The U.S. Food and Drug Administration (FDA) put the emergency use authorization for blood plasma as a COVID-19 Treatment on hold, reported The New York Times.
A COVID-19 vaccine is something the world awaits the most, but right now, the next big treatment to fight the pandemic could come from antibodies designed to attack this new virus.
Nonprofit organization American Civil Liberties Union (ACLU) is urging U.S. Congress to include millions of undocumented immigrants in the coronavirus disease 2019 (COVID-19) test under emergency coverage of Medicaid.
to swiftly act and pass legislation
test as millions of them play essential jobs in the country.
Recent studies show that antimalarial drugs chloroquine and hydroxychloroquine did not prevent patients from being infected with the coronavirus. Officials also claim the benefits did not outweigh the risks of taking the treatment.
The anti-malaria drug promoted by United States President Donald Trump failed to prevent people from contracting the COVID-19 disease. Scientists from the University of Minnesota and Canada conducted a study involving 821 people who had been exposed to the virus.
Researchers are now studying widely prescribed cardiovascular drugs after early findings revealed it could prevent or reduce complication in COVID-19 patients and help boost recovery.
The normally obscure blood business is booming as various research and medical institutions are in a raced to develop tests, therapies and vaccines which many believe to be the key to successfully easing lockdowns and eradicating the threat of the coronavirus pandemic.
Scientists researching hydroxychloroquine claims the publicity surrounding the drug is hampering studies on whether or not it can be used to treat COVID-19 patients.